Zimmer Biomet 10-Q Details Q3 Earnings Dip, New $60M Plant Restructuring and $755M of Acquisitions
ZBH sits 39% above its 52-week low of $79.12 on elevated volume (3.0× avg).
Summary
Zimmer Biomet's Q3 10-Q shows net earnings of $191.6 million (down from $230.9 million) on sales of $2.06 billion, plus a new ~$60 million manufacturing restructuring and about $755 million of acquisitions closed in the quarter.
Key Events · Earnings and Guidance · ZBH
-
Q3 Sales Up 3.1%, Earnings Down
Net sales were $2,062.9 million versus $2,001.4 million a year ago, but net earnings fell to $191.6 million from $230.9 million and diluted EPS to $1.00 from $1.16.
-
Operating Margin Compressed on SG&A
Operating profit dropped to $307.6 million from $351.3 million as SG&A rose to $855.0 million from $811.4 million, partly on higher litigation costs ($17.8 million in the quarter).
-
New Manufacturing Restructuring Plan
The September 2026 Manufacturing Network Optimization Plan carries about $60 million of exit costs, mostly severance from exiting part of the Winterthur, Switzerland facility by the end of 2028; $36.5 million was recognized year-to-date.
-
$755M of Acquisitions Closed in Q3
Iovera ($74.6 million cash), Monteris ($193.3 million cash) and Alafair ($112.6 million cash plus $185.7 million deferred to Q1 2027) totaled $754.9 million of consideration, adding $418.2 million of goodwill.
Analysis · ZBH · Industrial Applications And Services
The headline numbers were already out this morning, but the full 10-Q shows the quarter's quality is weaker than the adjusted-EPS beat suggests: operating profit fell to $307.6 million from $351.3 million a year ago as SG&A climbed to $855.0 million, and net earnings dropped to $191.6 million from $230.9 million. Against that, the company disclosed a new Manufacturing Network Optimization Plan (about $60 million of exit costs, mostly severance tied to exiting part of the Winterthur, Switzerland plant by the end of 2028) and roughly $755 million of fair value for three bolt-on deals closed in the quarter — Iovera, Monteris and Alafair — with $185.7 million of the Alafair price deferred into Q1 2027. The Global Foot and Ankle reporting unit, built almost entirely on the 2025 Paragon 28 deal, now has only about 5% of fair-value cushion over carrying value, which puts goodwill impairment risk on the table if foot-and-ankle forecasts slip. Cash generation remains solid at $1,367.2 million for nine months, funding $579.3 million of buybacks.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZBH was trading at $110.15 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $21B. The 52-week trading range was $79.12 to $112.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.